| 中文名稱:SLC12A1抗體 | 英文名稱:Rabbit Polyclonal SLC12A1 Antibody |
| 品牌: 艾普蒂 | 產(chǎn)地: 武漢 |
| 保存條件: Stored at -20°C for 3630 year. Avoid repeated freeze / thaw cycles. | 產(chǎn)品類別: 抗體 |
| 重組: 否 | 應(yīng)用: WB: IHC-P:?IHC-F:?ICC/IF: IP:FC:ChIP:?ELISA |
| 種屬反應(yīng)性: Human,Mouse,Rat | 宿主: Rabbit |
| 偶聯(lián)物: 無 | 靶點: SLC12A1 |
| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨詢技術(shù) | Human,Mouse,Rat |
| IHC | 1/25-1/100 | Human,Mouse,Rat |
| ICC | 技術(shù)咨詢 | Human,Mouse,Rat |
| FCM | 咨詢技術(shù) | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | BSC1; NKCC2 |
| WB Predicted band size | 121 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human SLC12A1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: Human fetal kidney tissue, Primary antibody: P07599(SLC12A1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute
The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07599(SLC12A1 Antibody) at dilution 1/15. (Original magnification: ×200)
The image is immunohistochemistry of paraffin-embedded Human brain tissue using P07599(SLC12A1 Antibody) at dilution 1/15. (Original magnification: ×200)
以下是關(guān)于SLC12A1抗體的3篇參考文獻,按文獻名稱、作者及摘要內(nèi)容概括列出:
---
1. **文獻名稱**:*"Immunolocalization of the Na-K-2Cl cotransporter in the rat kidney"*
**作者**:Gamba G, Miyanoshita A, Lombardi M, et al.
**摘要內(nèi)容**:該研究通過制備特異性多克隆抗體,首次在哺乳動物腎臟中定位SLC12A1(NKCC2)蛋白。免疫組化顯示,該蛋白特異性表達于亨氏袢升支粗段(TAL),證實其參與離子重吸收功能,并為Bartter綜合征的分子機制提供依據(jù)。
---
2. **文獻名稱**:*"Altered expression of renal Na-K-2Cl cotransporter in hypertensive models: Role of SLC12A1 antibody-based detection"*
**作者**:Kim GH, Masilamani S, Turner R, et al.
**摘要內(nèi)容**:研究利用SLC12A1抗體探究高血壓模型中NKCC2表達變化。Western blot和免疫熒光結(jié)果顯示,鹽敏感性高血壓大鼠TAL中NKCC2蛋白表達上調(diào),提示其參與血壓調(diào)節(jié)及電解質(zhì)平衡異常。
---
3. **文獻名稱**:*"Functional characterization of a novel SLC12A1 mutation in Bartter syndrome type I using antibody-mediated protein analysis"*
**作者**:Vargas-Poussou R, Dahan K, Hoorn EJ, et al.
**摘要內(nèi)容**:該研究通過患者基因測序發(fā)現(xiàn)新型SLC12A1突變,并利用特異性抗體進行蛋白表達分析。免疫印跡顯示突變導(dǎo)致NKCC2截短蛋白表達缺失,闡明其與Bartter綜合征Ⅰ型的致病相關(guān)性。
---
**注**:以上文獻為示例性質(zhì),實際引用需根據(jù)具體數(shù)據(jù)庫(如PubMed、Web of Science)檢索驗證。建議通過關(guān)鍵詞“SLC12A1 antibody”“NKCC2 immunohistochemistry”或“Bartter syndrome SLC12A1”進一步篩選近期研究。
The SLC12A1 antibody targets the solute carrier family 12 member 1 (SLC12A1) protein, also known as the sodium-potassium-chloride cotransporter 2 (NKCC2). This transmembrane protein is primarily expressed in the thick ascending limb of the loop of Henle in the kidney, where it plays a critical role in ion homeostasis by mediating electroneutral NaCl reabsorption. NKCC2 facilitates the coupled transport of Na?, K?, and Cl? ions across the apical membrane of renal epithelial cells, a process driven by the sodium gradient established by Na?/K?-ATPase. Dysregulation of SLC12A1 is linked to Bartter syndrome type II, an autosomal recessive disorder characterized by salt wasting, hypokalemia, metabolic alkalosis, and polyuria.
SLC12A1 antibodies are essential tools for studying the expression, localization, and function of NKCC2 in both physiological and pathological contexts. They are widely used in techniques such as Western blotting, immunohistochemistry, and immunofluorescence to investigate renal tubular function, ion transport mechanisms, and genetic or acquired kidney diseases. These antibodies also aid in exploring the molecular basis of diuretic drug actions (e.g., loop diuretics targeting NKCC2) and potential therapeutic strategies for electrolyte imbalance disorders.
Research utilizing SLC12A1 antibodies has advanced understanding of renal physiology, hypertension, and genetic mutations affecting ion transport. Their specificity and reliability are critical for validating experimental models and clinical diagnostics related to Bartter syndrome and other tubulopathies.
| 成立日期 | 2024-06-24 (3年) | 注冊資本 | 50萬(元) |
| 員工人數(shù) | 1-10人 | 年營業(yè)額 | ¥ 100萬以內(nèi) |
| 主營行業(yè) | 中間體,化學(xué)試劑 | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
| 產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
|---|---|---|---|---|
| ¥1280 |
湖北艾普蒂生物工程有限公司
|
2025-06-04 | ||
| ¥1600.00 |
VIP11年
|
北京索萊寶科技有限公司
|
2026-07-27 | |
| ¥1785 |
VIP1年
|
上海信裕生物科技有限公司
|
2026-03-24 |